The average institutional investor has up to 30% of their portfolio in alternative assets, compared with 5% for individuals, despite the benefits of diversification across asset classes.
With Bioverge, you can diversify across technology types, disease areas, and stage of development.
As an asset class, venture capital has generated attractive risk-adjusted returns over time, which can help you achieve your long-term financial goals.
The median net IRR for early-stage healthcare venture capital funds is 19.2%, suggesting these investments have a high potential for returns.1
Venture capital does not typically suffer from daily price fluctuations. Its low correlation to both stock and bond markets can provide portfolio stability.
Investments may qualify for long-term capital gains tax treatment, and QSBS tax benefits, which can provide up to a 100% break on capital gains taxes.
Bioverge is leveraging an artificial intelligence-driven diligence process to select the most compelling early-stage healthcare investment opportunities
Invest in a healthcare venture capital fund that reduces barriers to institutional-quality assets more efficiently and with low fees.
Invest alongside top-tier venture funds, at the same terms.
Invest in a healthcare venture capital fund that reduces barriers to institutional-quality assets more efficiently and with low fees.
Invest alongside top-tier venture funds, at the same terms.
Bioverge offers investment access and typically charges lower fees than most venture capital firms.